These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 35545089)
1. PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease. Park H; Kam TI; Peng H; Chou SC; Mehrabani-Tabari AA; Song JJ; Yin X; Karuppagounder SS; Umanah GK; Rao AVS; Choi Y; Aggarwal A; Chang S; Kim H; Byun J; Liu JO; Dawson TM; Dawson VL Cell; 2022 May; 185(11):1943-1959.e21. PubMed ID: 35545089 [TBL] [Abstract][Full Text] [Related]
2. Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition. Patel J; Dawson VL; Dawson TM Mov Disord; 2024 Apr; 39(4):644-650. PubMed ID: 38396375 [TBL] [Abstract][Full Text] [Related]
3. Allosteric Inhibitors of Macrophage Migration Inhibitory Factor (MIF) Interfere with Apoptosis-Inducing Factor (AIF) Co-Localization to Prevent Parthanatos. Chen D; Osipyan A; Adriana J; Kader M; Gureev M; Knol CWJ; Sigmund MC; Xiao Z; van der Wouden PE; Cool RH; Poelarends GJ; Dekker FJ J Med Chem; 2023 Jul; 66(13):8767-8781. PubMed ID: 37352470 [TBL] [Abstract][Full Text] [Related]
4. Macrophage migration inhibitor factor (MIF): Potential role in cognitive impairment disorders. Zeng L; Hu P; Zhang Y; Li M; Zhao Y; Li S; Luo A Cytokine Growth Factor Rev; 2024 Jun; 77():67-75. PubMed ID: 38548489 [TBL] [Abstract][Full Text] [Related]
5. Amelioration of pathologic α-synuclein-induced Parkinson's disease by irisin. Kam TI; Park H; Chou SC; Van Vranken JG; Mittenbühler MJ; Kim H; A M; Choi YR; Biswas D; Wang J; Shin Y; Loder A; Karuppagounder SS; Wrann CD; Dawson VL; Spiegelman BM; Dawson TM Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2204835119. PubMed ID: 36044549 [TBL] [Abstract][Full Text] [Related]
6. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Wang Y; An R; Umanah GK; Park H; Nambiar K; Eacker SM; Kim B; Bao L; Harraz MM; Chang C; Chen R; Wang JE; Kam TI; Jeong JS; Xie Z; Neifert S; Qian J; Andrabi SA; Blackshaw S; Zhu H; Song H; Ming GL; Dawson VL; Dawson TM Science; 2016 Oct; 354(6308):. PubMed ID: 27846469 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of macrophage migration inhibitory factor (MIF), a novel target to protect neurons from parthanatos induced by simulated post-spinal cord injury oxidative stress. Yang D; Shu T; Zhao H; Sun Y; Xu W; Tu G Biochem Biophys Res Commun; 2020 Mar; 523(3):719-725. PubMed ID: 31948762 [TBL] [Abstract][Full Text] [Related]
8. The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. Liu L; Li J; Ke Y; Zeng X; Gao J; Ba X; Wang R Cell Mol Life Sci; 2022 Jan; 79(1):60. PubMed ID: 35000037 [TBL] [Abstract][Full Text] [Related]
9. MIF promotes neurodegeneration and cell death via its nuclease activity following traumatic brain injury. Ruan Z; Lu Q; Wang JE; Zhou M; Liu S; Zhang H; Durvasula A; Wang Y; Wang Y; Luo W; Wang Y Cell Mol Life Sci; 2021 Dec; 79(1):39. PubMed ID: 34921640 [TBL] [Abstract][Full Text] [Related]
10. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein. Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656 [TBL] [Abstract][Full Text] [Related]
11. A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease. Kwon SH; Kim S; Park AY; Lee S; Gadhe CG; Seo BA; Park JS; Jo S; Oh Y; Kweon SH; Ma SX; Kim WR; Kim M; Kim H; Kim JE; Lee S; Lee J; Ko HS J Med Chem; 2021 Oct; 64(20):15091-15110. PubMed ID: 34583507 [TBL] [Abstract][Full Text] [Related]
12. Reelin protects against pathological α-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease. Cho E; Kim K; Kim H; Cho SR Neurobiol Dis; 2022 Dec; 175():105898. PubMed ID: 36270619 [TBL] [Abstract][Full Text] [Related]
13. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665 [TBL] [Abstract][Full Text] [Related]
15. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease. Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147 [TBL] [Abstract][Full Text] [Related]
16. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Sharma N; Rao SP; Kalivendi SV Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974 [TBL] [Abstract][Full Text] [Related]
17. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease. Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873 [TBL] [Abstract][Full Text] [Related]
18. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735 [TBL] [Abstract][Full Text] [Related]
19. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease. Nasiri E; Sankowski R; Dietrich H; Oikonomidi A; Huerta PT; Popp J; Al-Abed Y; Bacher M Mol Med; 2020 Apr; 26(1):34. PubMed ID: 32303185 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson's disease. Kim S; Choi JG; Kim SW; Park SC; Kang YR; Park DS; Son M; Lee CH Biomed Pharmacother; 2022 Oct; 154():113637. PubMed ID: 36058149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]